Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

574.06 USD +16.60 (+2.98%)
Official Closing Price Updated: 7:40 PM EDT, Sep 25, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 643,600
Open 555.40
Bid (Size) 550.00 (1)
Ask (Size) 574.00 (2)
Prev. Close 557.46
Today's Range 551.00 - 575.91
52wk Range 271.37 - 664.64
Shares Outstanding 105,949,824
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
From PR Newswire
Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
From GlobeNewswire News Releases

Performance

YTD
+53.76%
+53.76%
1 Month
-6.20%
-6.20%
3 Month
-6.10%
-6.10%
6 Month
+27.71%
+27.71%
1 Year
+104.07%
+104.07%

More News

Read More
Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
From GlobeNewswire News Releases
Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO
From PR Newswire
Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO
From GlobeNewswire News Releases
S&P 500 Buybacks Decline 55.4% to $88.7 Billion; Significant Reductions Expected to continue in Q3 2020
From PR Newswire
Imanis Life Sciences to Present IMMUNO-COV, a First-in-Class Neutralizing Antibody Test for COVID-19, at American Society of Gene and Cell Therapy Symposium
From GlobeNewswire News Releases
RECOVERY COVID-19 Phase 3 Trial to Evaluate Regeneron's REGN-COV2 Investigational Antibody Cocktail in the UK
From PR Newswire
FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis
From GlobeNewswire News Releases
FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis
From PR Newswire
Noteworthy ETF Outflows: USMV, RSG, WM, REGN
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.